Pharmaceutical policies in the long run: reflections on 60th anniversary of the Hinchliffe Report
Monday, 11 November 2019, 9.30am to 5pm
Merton College, Merton Street Oxford, OX1 4JD
A symposium organised by the Nuffield Department of Population Health to mark the 60th anniversary of the Hinchliffe Report - by a government committee which examined the rise in pharmaceutical expenditure following the introduction of the NHS. The report's far-reaching recommendations include:
- Improvements in the training of GPs to understand evidence regarding the use of new drugs and the economics of prescribing
- Routinely conducting clinical trials to assess drugs and to publish results in an independent prescribers’ journal
- Development of an expert body that would be informed by research on economic and social aspects of the NHS
- An examination of the economics of drug development, marketing and pharmacy to ensure efficiency and equity in prescribing.
The workshop will reflect on the degree to which we face similar challenges today, and the extent to which these challenges have been addresed. It will also consider whether if a report to look at pharmaceutical expenditure today were to be commissioned, what potential long-term recommendations could be made to address current challenges.
CONFIRMED SPEAKERS INCLUDE
- Dr Amanda Adler, Chair of NICE Appraisal Committee and Consultant Physician
- Prof Louise Bowman, Professor of Medicine and Clinical Trials, Clinical Trials at the Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford
- Prof Philip Clarke, Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford
- Prof Sir Rory Collins, Head of Nuffield Department of Population Health and BFH Professor of Medicine and Epidemiology
- Sir Andrew Dillon, CEO, National Institute for Health and Care Excellence
- Dr Elaine Kelly, Senior Research Economist, Institute of Fiscal Studies and the Health Foundation
- Prof Martin Landray, Big Data Institute, Nuffield Department of Population Health, University of Oxford
- Mr Danny Palnoch, Head of Medicines Analysis, Strategy and Policy, NHS England
- Prof Adrian Towse, Office of Health Economics